TXP Peptides Provide the Opportunity to Develop Unique Assets Tailored to the Target Disease and Patient Population
SynAct Pharma has expanded its melanocortin agonist portfolio through the acquisition of TXP Pharma AG.
TXP Pharma had created a platform of more than 70 unique analogues of the naturally occurring melanocyte stimulation hormone (MSH) with a range of melanocortin receptor selectivity. The TXP-analogues have both increased stability as well as enhanced receptor binding and stimulation over MSH.
This provides SynAct Pharma with a range of potential new compounds to develop.
TXP-11 has completed regulatory toxicology studies required to initiate Phase I studies in humans. TXP-11 is a peptide which is administered intravenously and is expected to be used for prevention of organ failure in relation to major surgeries.